LeMaitre Vascular (LMAT) 10-Q 6 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Jul. 31, 2019
Document Information [Line Items]
Entity Registrant Name	LEMAITRE VASCULAR INC
Entity Central Index Key	0001158895
Trading Symbol	lmat
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding (in shares)		19,846,966
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 13,264	$ 26,318
Short-term marketable securities	34,979	21,668
Accounts receivable, net of allowances of $460 at June 30, 2019 and $399 at December 31, 2018	15,548	15,721
Inventory and other deferred costs	32,243	27,388
Prepaid expenses and other current assets	2,125	2,922
Total current assets	98,159	94,017
Property and equipment, net	14,163	14,102
Right-of-use leased assets	6,428
Goodwill	29,860	29,868
Other intangibles, net	12,632	13,692
Deferred tax assets	1,209	1,215
Other assets	210	194
Total assets	162,661	153,088
Liabilities and stockholders’ equity
Accounts payable	1,427	1,732
Accrued expenses	12,097	15,847
Acquisition-related obligations	2,200	2,179
Lease liabilities - short-term	1,698
Total current liabilities	17,422	19,758
Lease liabilities - long-term	5,152
Deferred tax liabilities	484	484
Other long-term liabilities	2,066	2,611
Total liabilities	25,124	22,853
Stockholders’ equity:
Preferred stock, $0.01 par value; authorized 3,000,000 shares; none outstanding
Common stock, $0.01 par value; authorized 37,000,000 shares; issued 21,250,872 shares at June 30, 2019, and 21,110,224 shares at December 31, 2018	213	211
Additional paid-in capital	100,890	98,442
Retained earnings	50,624	45,831
Accumulated other comprehensive loss	(3,818)	(3,900)
Treasury stock, at cost; 1, 502,519 shares at June 30, 2019 and 1,501,511 shares at December 31, 2018	(10,372)	(10,349)
Total stockholders’ equity	137,537	130,235
Total liabilities and stockholders’ equity	$ 162,661	$ 153,088

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Accounts receivable, allowances	$ 460	$ 399
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	3,000,000	3,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	37,000,000	37,000,000
Common stock, shares issued (in shares)	21,250,872	21,110,224
Treasury stock, at cost (in shares)	1,502,519	1,501,511

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net Sales	$ 29,483	$ 27,020	$ 57,962	$ 53,014
Cost of sales	9,168	8,028	18,183	15,548
Gross profit	20,315	18,992	39,779	37,466
Sales and marketing	7,613	6,792	15,458	13,882
General and administrative	4,531	4,547	9,475	9,244
Research and development	2,256	1,988	4,496	3,813
Gain on divestiture		(5,876)		(5,876)
Total operating expenses	14,400	7,451	29,429	21,063
Income from operations	5,915	11,541	10,350	16,403
Other income (expense):
Interest income	224	165	381	260
Foreign currency gain (loss)	(51)	(159)	(130)	(200)
Income before income taxes	6,088	11,547	10,601	16,463
Provision for income taxes	1,464	2,796	2,464	3,859
Net income	$ 4,624	$ 8,751	$ 8,137	$ 12,604
Earnings per share of common stock:
Basic (in dollars per share)	$ 0.23	$ 0.45	$ 0.41	$ 0.65
Diluted (in dollars per share)	$ 0.23	$ 0.43	$ 0.40	$ 0.62
Weighted-average shares outstanding:
Basic (in shares)	19,680	19,320	19,660	19,301
Diluted (in shares)	20,246	20,260	20,226	20,243
Cash dividends declared per common share (in dollars per share)	$ 0.085	$ 0.07	$ 0.17	$ 0.14

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net income	$ 4,624	$ 8,751	$ 8,137	$ 12,604
Other comprehensive income (loss):
Foreign currency translation adjustment, net	208	(1,223)	(53)	(895)
Unrealized gain (loss) on short-term marketable securities	66	22	135	(23)
Total other comprehensive income (loss)	274	(1,201)	82	(918)
Comprehensive income	$ 4,898	$ 7,550	$ 8,219	$ 11,686

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2017	20,745,041				1,480,101
Balance at Dec. 31, 2017	$ 207	$ 93,127	$ 28,333	$ (2,289)	$ (9,608)	$ 109,770
Net income			3,853			3,853
Other comprehensive income				283		283
Issuance of common stock for stock options exercised (in shares)	34,826
Issuance of common stock for stock options exercised	$ 1	292				293
Stock-based compensation expense		621				621
Repurchase of common stock at cost (in shares)
Repurchase of common stock at cost
Common stock dividend accrued			(1,350)			(1,350)
Balance (in shares) at Mar. 31, 2018	20,779,867				1,480,101
Balance at Mar. 31, 2018	$ 208	94,040	30,836	(2,006)	$ (9,608)	113,470
Balance (in shares) at Dec. 31, 2017	20,745,041				1,480,101
Balance at Dec. 31, 2017	$ 207	93,127	28,333	(2,289)	$ (9,608)	109,770
Net income						12,604
Other comprehensive income						(918)
Balance (in shares) at Jun. 30, 2018	20,836,847				1,480,250
Balance at Jun. 30, 2018	$ 208	95,122	38,234	(3,207)	$ (9,613)	120,744
Balance (in shares) at Mar. 31, 2018	20,779,867				1,480,101
Balance at Mar. 31, 2018	$ 208	94,040	30,836	(2,006)	$ (9,608)	113,470
Net income			8,751			8,751
Other comprehensive income				(1,201)		(1,201)
Issuance of common stock for stock options exercised (in shares)	56,215
Issuance of common stock for stock options exercised		446				446
Vested restricted stock units (in shares)	765
Vested restricted stock units
Stock-based compensation expense		636				636
Repurchase of common stock at cost (in shares)					149
Repurchase of common stock at cost					$ (5)	(5)
Common stock dividend accrued			(1,353)			(1,353)
Balance (in shares) at Jun. 30, 2018	20,836,847				1,480,250
Balance at Jun. 30, 2018	$ 208	95,122	38,234	(3,207)	$ (9,613)	120,744
Balance (in shares) at Dec. 31, 2018	21,110,224				1,501,511
Balance at Dec. 31, 2018	$ 211	98,442	45,831	(3,900)	$ (10,349)	130,235
Net income			3,513			3,513
Other comprehensive income				(192)		(192)
Issuance of common stock for stock options exercised (in shares)	61,419
Issuance of common stock for stock options exercised	$ 1	478				479
Vested restricted stock units (in shares)	2,026
Vested restricted stock units
Stock-based compensation expense		746				746
Repurchase of common stock at cost (in shares)					926
Repurchase of common stock at cost					$ (21)	(21)
Common stock dividend accrued			(1,672)			(1,672)
Balance (in shares) at Mar. 31, 2019	21,173,669				1,502,437
Balance at Mar. 31, 2019	$ 212	99,666	47,672	(4,092)	$ (10,370)	133,088
Balance (in shares) at Dec. 31, 2018	21,110,224				1,501,511
Balance at Dec. 31, 2018	$ 211	98,442	45,831	(3,900)	$ (10,349)	130,235
Net income						8,137
Other comprehensive income						82
Balance (in shares) at Jun. 30, 2019	21,250,872				1,503,445
Balance at Jun. 30, 2019	$ 213	100,890	50,624	(3,818)	$ (10,372)	137,537
Balance (in shares) at Mar. 31, 2019	21,173,669				1,502,437
Balance at Mar. 31, 2019	$ 212	99,666	47,672	(4,092)	$ (10,370)	133,088
Net income			4,624			4,624
Other comprehensive income				274		274
Issuance of common stock for stock options exercised (in shares)	77,032
Issuance of common stock for stock options exercised	$ 1	530				531
Vested restricted stock units (in shares)	171
Vested restricted stock units
Stock-based compensation expense		694				694
Repurchase of common stock at cost (in shares)					1,008
Repurchase of common stock at cost					$ (2)	(2)
Common stock dividend accrued			(1,672)			(1,672)
Balance (in shares) at Jun. 30, 2019	21,250,872				1,503,445
Balance at Jun. 30, 2019	$ 213	$ 100,890	$ 50,624	$ (3,818)	$ (10,372)	$ 137,537

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating activities
Net income	$ 8,137	$ 12,604
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,630	2,102
Stock-based compensation	1,440	1,257
Fair value adjustment to contingent consideration obligations	79	42
Provision for doubtful accounts	219	146
Provision for inventory write-downs	402	170
Gain on divestitures		(5,876)
Foreign currency transaction loss	(63)	96
Changes in operating assets and liabilities:
Accounts receivable	(62)	(552)
Inventory and other deferred costs	(5,288)	(1,306)
Prepaid expenses and other assets	715	26
Accounts payable and other liabilities	(4,094)	(82)
Net cash provided by operating activities	4,115	8,627
Investing activities
Purchases of property and equipment and other assets	(1,651)	(1,230)
Purchases of short-term marketable securities	(13,175)	(10,757)
Proceeds from divestuture		7,400
Net cash used in investing activities	(14,826)	(4,587)
Financing activities
Payments of deferred acquisition consideration	(59)	(1,142)
Proceeds from issuance of common stock	1,008	738
Purchase of treasury stock	(23)	(5)
Common stock cash dividend paid	(3,344)	(2,704)
Net cash provided by financing activities	(2,418)	(3,113)
Effect of exchange rate changes on cash and cash equivalents	75	(385)
Net increase in cash and cash equivalents	(13,054)	542
Cash and cash equivalents at beginning of period	26,318	19,096
Cash and cash equivalents at end of period	$ 13,264	$ 19,638

Note 1 - Organization and Basis

Note 1 - Organization and Basis for Presentation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Description of Business Unless the context requires otherwise, references to LeMaitre Vascular, we, our, and us refer to LeMaitre Vascular, Inc. and our subsidiaries. We develop, manufacture, and market medical devices and implants used primarily in the field of vascular surgery. We also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. We operate in a single segment in which our principal product lines include the following: anastomotic clips, angioscopes, balloon catheters, biologic vascular grafts, biologic vascular patches, carotid shunts, polyester vascular grafts, powered phlebectomy devices, radiopaque marking tape, remote endarterectomy devices, surgical glue and valvulotomes. Our offices are located in Burlington, Massachusetts; Fox River Grove, Illinois; Chandler, Arizona; Vaughan, Canada; Sulzbach, Germany; Milan, Italy; Madrid, Spain; Saint-Etienne, France; North Melbourne, Australia; Tokyo, Japan; Shanghai, China and Singapore. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10 -Q and Article 10 of Regulation S- X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal, recurring adjustments considered necessary for a fair presentation of the results of these interim periods have been included. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, sales returns and discounts, share-based compensation, and income taxes are updated as appropriate. The results for the six months ended June 30, 2019 are not necessarily indicative of results to be expected for the entire year. The information contained in these interim financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, 2018, including the notes thereto, included in our Form 10 -K filed with the Securities and Exchange Commission (SEC) on March 11, 2019. Consolidation Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Revenue Recognition Our revenue is derived primarily from the sale of disposable or implantable devices used during vascular surgery. We sell primarily directly to hospitals and to a lesser extent to distributors, as described below, and, during the periods presented in our consolidated financial statements, entered into consigned inventory arrangements with either hospitals or distributors on a limited basis. With the acquisition of the RestoreFlow allograft business, we also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. These revenues are recognized when services have been provided and the tissue has been shipped to the customer, provided all other revenue recognition criteria discussed in the succeeding paragraph have been met. We recognize revenue under the provisions of ASU 2014 - 09, Revenue from Contracts with Customers (Topic 606 ) . The core principle of Topic 606 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard explains that to achieve the core principle, an entity should take the following actions: Step 1: Identify the contract with a customer Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price Step 4: Allocate the transaction price Step 5: Recognize revenue when or as the entity satisfies a performance obligation Revenue is recognized when or as a company satisfies a performance obligation by transferring a promised good or service to a customer (which is when the customer obtains control of that good or service). In instances in which shipping and handling activities are performed after a customer takes control of the goods (such as when title passes upon shipment from our dock), we have made the policy election allowed under Topic 606 to account for these activities as fulfillment costs and not as performance obligations. We generally reference customer purchase orders to determine the existence of a contract. Orders that are not accompanied by a purchase order are confirmed with the customer either in writing or verbally. The purchase orders or similar correspondence, once accepted, identify the performance obligations as well as the transaction price, and otherwise outline the rights and obligations of each party. We allocate the transaction price of each contract among the performance obligations in accordance with the pricing of each item specified on the purchase order, which is in turn based on standalone selling prices per our published price lists. In cases where we discount products or provide certain items free of charge, we allocate the discount proportionately to all performance obligations, unless it can be demonstrated that the discount should be allocated entirely to one or more, but not all, of the performance obligations. We recognize revenue, net of allowances for returns and discounts, fees paid to group purchasing organizations, and any sales and value added taxes required to be invoiced, which we have elected to exclude from the measurement of the transaction price as allowed by the standard, at the time of shipment (taking into consideration contractual shipping terms), or in the case of consigned inventory, when it is consumed. Shipment is the point at which control of the product and title passes to our customers, and at which LeMaitre Vascular has a present right to receive payment for the goods. Below is a disaggregation of our revenue by major geographic area, which is among the primary categorizations used by management in evaluating financial performance, for the periods indicated (in thousands): Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 ($ in thousands) ($ in thousands) Americas $ 17,511 $ 16,082 $ 33,886 $ 31,942 Europe, Middle East and Africa 10,014 9,074 20,027 17,829 Asia/Pacific Rim 1,958 1,864 4,049 3,243 Total $ 29,483 $ 27,020 $ 57,962 $ 53,014 Except as discussed in Note 7, we do not carry any contract assets or contract liabilities, as there are generally no unbilled amounts due from customers under contracts for which we have partially satisfied performance obligations, or amounts received from customers for which we have not satisfied performance obligations. We satisfy our performance obligations under revenue contracts within a very short time period from receipt of the orders, and payments from customers are typically received within 30 to 60 days of fulfillment of the orders, except in certain geographies such as Spain and Italy where the payment cycle is customarily longer. Accordingly, there is no significant financing component to our revenue contracts. Additionally, we have elected as a policy that incremental costs (such as commissions) incurred to obtain contracts are expensed as incurred, due to the short-term nature of the contracts. Customers returning products may be entitled to full or partial credit based on the condition and timing of the return. To be accepted, a returned product must be unopened (if sterile), unadulterated, and undamaged, must have at least 18 months remaining prior to its expiration date, or twelve months for our hospital customers in Europe, and generally be returned within 30 days of shipment. These return policies apply to sales to both hospitals and distributors. The amount of products returned to us, either for exchange or credit, has not been material. Nevertheless, we provide for an allowance for future sales returns based on historical return experience, which requires judgment. Our cost of replacing defective products has not been material and is accounted for at the time of replacement. Recent Accounting Pronouncements On January 1, 2019 we adopted the provisions of ASU No. 2016 - 02, Leases (Topic 842 ), subsequently amended by ASU 2018 - 11, Leases (Topic 842 ): Targeted Improvements . Under the new guidance, we are required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. As allowed by the standard, we elected to use the transition option not to apply the new lease standard to comparative periods but instead to recognize a cumulative-effect adjustment to retained earnings as of the date of adoption, January 1, 2019. Upon adoption of this standard, we recognized lease liabilities of $7.0 million and right-of-use assets in the amount of $6.5 million (net of the reversal of a previously recorded deferred rent liability of $0.5 million). There was no cumulative-effect adjustment to retained earnings required. Additional disclosures required under the new standard are included in Note 6 to these financial statements. In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2018 - 15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350 - 40 ) , which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The new standard is effective for us beginning January 1, 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial statements. In August 2018, the FASB issued ASU 2018 - 13 Fair Value Measurement (Topic 820 ), which modifies the disclosure requirements for fair value measurements. The new standard is effective for us beginning January 1, 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial statements. In January 2017, the FASB issued ASU 2017 - 04, which, among other provisions, eliminates “step 2” from the goodwill impairment test. The annual, or interim, goodwill impairment test will be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The new standard is effective for us beginning January 1, 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial statements. In June 2016, the FASB issued ASU No. 2016 - 13, Financial Instruments – Credit Losses (Topic 326 ): Measurement of Credit Losses on Financial Instruments (“ASU 2016 - 13” ), which modifies the measurement of expected credit losses of certain financial instruments, including accounts receivable. The new standard is effective for us beginning January 1, 2020, with early adoption permitted. The adoption of this standard is not expected to have a material impact on our financial statements.

Note 2 - Income Tax Expense

Note 2 - Income Tax Expense	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	2. As part of the process of preparing our consolidated financial statements we are required to determine our income taxes in each of the jurisdictions in which we operate. This process involves estimating our actual current tax expense together with assessing temporary differences resulting from recognition of items for income tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheet. We must then assess the likelihood that our deferred tax assets will be recovered from taxable income during the carryback period or in the future; and to the extent we believe that recovery is not not, not We recognize, measure, present and disclose in our financial statements any uncertain tax positions that we have taken, or expect to take on a tax return. We operate in multiple taxing jurisdictions, both within and without the United States, and may Our policy is to classify interest and penalties related to unrecognized tax benefits as income tax expense. Our 2019 first 2019, 2018 We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of June 30, 2019, $753,000. 2026. Six months ended June 30, 2019 (in thousands) Unrecognized tax benefits as of December 31, 2018 $ 711 Additions for tax positions of current year 37 Additions for tax positions of prior years 5 Reductions for settlements with taxing authorities - Reductions for lapses of the applicable statutes of limitations - Unrecognized tax benefits as of June 30, 2019 $ 753 As of June 30, 2019, United States 2015 Foreign 2012

Note 3 - Inventories and Other

Note 3 - Inventories and Other Deferred Costs	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Inventory and Other Deferred Costs Disclosure [Text Block]	3. Inventories and other deferred costs consist of the following: June 30, 2019 December 31, 2018 (in thousands) Raw materials $ 4,399 $ 4,085 Work-in-process 5,477 5,095 Finished products 18,824 16,391 Other deferred costs 3,544 1,817 Total inventory and other deferred costs $ 32,243 $ 27,388 We had inventory on consignment of $1.9 $1.7 June 30, 2019 December 31, 2018, Other deferred costs relate to our RestoreFlow allograft offering and include costs incurred for the preservation of human vascular tissues available for shipment, tissues currently in active processing, and tissues held in quarantine pending release to implantable status. By federal law, human tissues cannot be bought or sold. Therefore, the vascular tissues we preserve are not

Note 4 - Acquisitions and Dives

Note 4 - Acquisitions and Divestitures	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Business Combination Disclosure [Text Block]	4. Our acquisitions are accounted for using the acquisition method, and the acquired companies’ results have been included in the accompanying consolidated financial statements from their respective dates of acquisition. In each case for the acquisitions disclosed below, pro forma information assuming the acquisition had occurred at the beginning of the earliest period presented is not With the exception of Cardial discussed below, our acquisitions have historically been made at prices above the fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of synergies that will be realized by combining businesses. These synergies include the use of our existing sales channel to expand sales of the acquired businesses’ products and services, consolidation of manufacturing facilities, and the leveraging of our existing administrative infrastructure. The fair market valuations associated with these transactions fall within Level 3 3 13 Cardial On October 22, 2018, The purchase price for the acquired assets, including the land and building, inventory, machinery and equipment, intellectual property, permits and approvals, data and records, and customer and supplier information, was €2.0 $2.3 €1.1 $1.3 €0.5 $0.5 €0.4 $0.4 two twelve eighteen no may The following table summarizes the preliminary purchase price allocation: Allocated Fair Value (in thousands) Inventory € 2,419 Land and building 750 Equipment and supplies 94 Intangible assets 623 Bargain purchase gain (1,946 ) Purchase price € 1,940 The bargain purchase gain was recorded to reflect the excess of the net assets acquired over the purchase price. We recorded deferred taxes on this gain of €0.5 $0.6 €1.4 $1.6 The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives: Allocated Fair Value Weighted Average Useful Life (in thousands) (in years) Customer relationships € 250 16.0 Intellectual property 237 5.0 Non-compete agreement 46 5.0 Tradenames 90 5.0 Total intangible assets € 623 The weighted-average amortization period of the acquired intangible assets was 9.4 Applied Medical On September 20, 2018, 60% 40% twelve The purchase price for the acquired assets, which included inventory, machinery and equipment, intellectual property, permits and approvals, data and records, and customer and supplier information, was $14.2 $11 $2 12 $1.2 24 $3.2 $3.0 3.75% no may The following table summarizes the purchase price allocation: Allocated Fair Value (in thousands) Inventory $ 739 Equipment and supplies 416 Intangible assets 6,527 Goodwill 6,361 Purchase price $ 14,043 The goodwill results from expected synergies of combining the acquired products and customer information to our existing operations, and is deductible for tax purposes over 15 The following table reflects the allocation of purchase consideration to the acquired intangible assets and related estimated useful lives: Allocated Fair Value Weighted Average Useful Life (in thousands) (in years) Customer relationships $ 4,475 16.0 Intellectual property 1,316 7.0 Non-compete agreement 530 5.0 Tradenames 206 7.0 Total intangible assets $ 6,527 The weighted-average amortization period of the acquired intangible assets was 13.0 Reddick Divestiture On April 5, 2018, $7.4 two six June 30, 2018 $5.9 Allocated Fair Value (in thousands) Inventory $ 308 Deferred revenue - transition services agreement 1,081 Goodwill 135 Gain on divestiture 5,876 Consideration received $ 7,400 Under the terms of the transition services agreement, we have agreed to manufacture the Reddick products for the buyer at prices at or in some cases below our cost. We allocated a portion of the consideration received to this agreement to reflect it at fair value and recorded it as deferred revenue. As the products are sold to the buyer, we amortize a portion of the deferred revenue to adjust the gross margin on the sale to fair value on a specific identification basis. As of June 30, 2019, $0.2 Subsequent Event On July 12, 2019, $8.0

Note 5 - Goodwill and Other Int

Note 5 - Goodwill and Other Intangibles	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	5. Goodwill consists of the following as of June 30, 2019: (in thousands) Balance at December 31, 2018 $ 29,868 Effects of currency exchange (8 ) Balance at June 30, 2019 $ 29,860 Other intangible assets consist of the following: June 30, 2019 December 31, 2018 Gross Net Gross Net Carrying Accumulated Carrying Carrying Accumulated Carrying Value Amortization Value Value Amortization Value (in thousands) Product technology and intellectual property $ 11,728 $ 6,252 $ 5,476 $ 11,728 $ 5,726 $ 6,002 Trademarks, tradenames and licenses 2,246 1,626 620 2,246 1,561 685 Customer relationships 10,093 3,920 6,173 10,065 3,806 6,259 Other intangible assets 2,143 1,780 363 2,145 1,399 746 Total identifiable intangible assets $ 26,210 $ 13,578 $ 12,632 $ 26,184 $ 12,492 $ 13,692 These intangible assets are being amortized over their useful lives ranging from 2 16 June 30, 2019 9.7 Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 (in thousands) (in thousands) Amortization expense $ 556 $ 414 $ 1,111 $ 832 We estimate that amortization expense for the remainder of 2019 five Year ended December 31, 2019 2020 2021 2022 2023 2024 (in thousands) Amortization expense $ 1,010 $ 1,857 $ 1,624 $ 1,420 $ 1,346 $ 1,182

Note 6 - Leases

Note 6 - Leases	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	6. We conduct the majority of our operations in leased facilities, all of which are accounted for as operating leases, as they do not three 27,098 27,289 15,642 fourth 12,878 December 2023. 16,470 3,630 2019, August 2023. two five five February 2023. September May, twelve None no no no June 30, 2019. We also lease automobiles under operating leases in the U.S. as well as certain of our international subsidiaries. The terms of these leases are generally three As discussed above under Recent Accounting Pronouncements, on January 1, 2019 No. 2016 02, Leases (Topic 842 2018 11, Leases (Topic 842 Our most significant judgment involved in determining the amounts to initially record as lease liabilities and right-of-use assets was the estimation of a discount rate; because we have no no 5.25%. Additional information with respect to our leases is as follows: Three months ended Six months ended June 30, 2019 June 30, 2019 (in thousands) (in thousands) Lease cost Operating lease cost $ 432 $ 854 Short-term lease cost 63 131 Total lease cost $ 495 $ 985 Other information Cash paid for amounts included in the measurement of operating lease liabilities $ 445 $ 959 Right-of-use assets obtained in exchange for new operating leae liabilities $ 594 $ 810 Weighted average remaining lease term - operating leases (in years) 4.1 4.1 Weighted average discount rate - operating leases (in years) 5.25 % 5.25 % At June 30, 2019, one Remainder of 2019 $ 1,080 Year ending December 31, 2020 1,997 2021 1,863 2022 1,522 2023 1,249 Adjustment to net present value as of June 30, 2019 (861 ) Minimum noncancelable lease liability $ 6,850

Note 7 - Accrued Expenses and O

Note 7 - Accrued Expenses and Other Long-term Liabilities	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]	7. Accrued expenses consist of the following: June 30, 2019 December 31, 2018 (in thousands) Compensation and related taxes $ 6,476 $ 7,973 Income and other taxes 1,230 2,927 Professional fees 111 43 Deferred revenue 188 552 Other 4,092 4,352 Total $ 12,097 $ 15,847 As discussed in Note 4 three six June 30, 2019: June 30, 2019 (in thousands) Beginning contract liability balance $ 552 Revenue recognized upon satisfaction of performance obligations in the period (364 ) Ending balance $ 188 Other long-term liabilities consist of the following: June 30, 2019 December 31, 2018 (in thousands) Aquisition-related liabilities $ 1,354 $ 1,326 Deferred rent - 530 Income taxes 566 559 Other 146 196 Total $ 2,066 $ 2,611

Note 8 - Segment and Enterprise

Note 8 - Segment and Enterprise-wide Disclosures	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	8. Under Accounting Standards Codification Topic 280, Segment Reporting one No Most of our revenues are generated in the United States, Germany, and other European countries as well as in Canada, Japan and China. Substantially all of our assets are located in the United States. Net sales to unaffiliated customers by country were as follows: Three months ended Six months ended June 30, June 30, 2019 2018 2019 2018 (in thousands) (in thousands) United States $ 16,006 $ 14,864 $ 30,764 $ 29,684 Germany 3,192 3,257 6,272 6,364 Other countries 10,285 8,899 20,926 16,966 Net Sales $ 29,483 $ 27,020 $ 57,962 $ 53,014

Note 9 - Share-based Compensati

Note 9 - Share-based Compensation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	9. Our Third Amended and Restated 2006 Three months ended Six months ended June 30, June 30, 2019 2018 2019 2018 (in thousands) (in thousands) Stock option awards $ 432 $ 391 $ 879 $ 780 Restricted stock units 262 245 561 477 Total share-based compensation $ 694 $ 636 $ 1,440 $ 1,257 Stock-based compensation is included in our statements of operations as follows: Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 (in thousands) (in thousands) Cost of sales $ 76 $ 83 $ 158 $ 148 Sales and marketing 146 136 304 273 General and administrative 418 351 837 702 Research and development 54 66 141 134 Total stock-based compensation $ 694 $ 636 $ 1,440 $ 1,257 We did not six June 30, 2019 2018. We issued approximately 141,000 92,000 six June 30, 2019 2018,

Note 10 - Net Income Per Share

Note 10 - Net Income Per Share	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	10. The computation of basic and diluted net income per share was as follows: Three months ended Six months ended June 30, June 30, 2019 2018 2019 2018 (in thousands, except per share data) (in thousands, except per share data) Basic: Net income available for common stockholders $ 4,624 $ 8,751 $ 8,137 $ 12,604 Weighted average shares outstanding 19,680 19,320 19,660 19,301 Basic earnings per share $ 0.23 $ 0.45 $ 0.41 $ 0.65 Diluted: Net income available for common stockholders $ 4,624 $ 8,751 $ 8,137 $ 12,604 Weighted-average shares outstanding 19,680 19,320 19,660 19,301 Common stock equivalents, if dilutive 566 940 566 942 Shares used in computing diluted earnings per common share 20,246 20,260 20,226 20,243 Diluted earnings per share $ 0.23 $ 0.43 $ 0.40 $ 0.62 Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive 531 214 537 214

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Share Repurchase Program On February 14, 2019, $10.0 may February 14, 2020, not Dividends In February 2011, Record Date Payment Date Per Share Amount Dividend Payment (in thousands) Fiscal Year 2019 March 22, 2019 April 5, 2019 $ 0.085 $ 1,672 May 22, 2019 June 5, 2019 $ 0.085 $ 1,672 Fiscal Year 2018 March 22, 2018 April 5, 2018 $ 0.070 $ 1,351 May 22, 2018 June 7, 2018 $ 0.070 $ 1,353 August 22, 2018 September 6, 2018 $ 0.070 $ 1,369 November 20, 2018 December 6, 2018 $ 0.070 $ 1,372 On July 22, 2019 $0.085 September 5, 2019 August 21, 2019 $1.7

Note 12 - Supplemental Cash Flo

Note 12 - Supplemental Cash Flow Information	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	12. Six Months Ended June 30. 2019 2018 (in thousands) Cash paid for income taxes, net $ 4,157 $ 3,140

Note 13 - Fair Value Measuremen

Note 13 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	13. The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one three • Level 1 • Level 2 1, not • Level 3 no Level 1 June 30, 2019 We had no 2 June 30, 2019. Several of our assets and liabilities related to prior acquisitions were measured using Level 3 2016, $5.1 $1.1 $4.0 first 12 24 $1.0 first 2018. not not three 10% $0.3 3 Six months ended June 30, 2019 2018 (in thousands) Beginning balance $ 72 $ 1,300 Additions - - Payments (59 ) (1,142 ) Change in fair value included in earnings (13 ) 42 Ending balance $ - $ 200

Note 14 - Accumulated Other Com

Note 14 - Accumulated Other Comprehensive Loss	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	14. Changes to our accumulated other comprehensive loss consisted primarily of foreign currency translation for the six June 30, 2019 2018 Six months ended June 30, 2019 2018 (in thousands) Beginning balance $ (3,900 ) $ (2,289 ) Other comprehensive income (loss) before reclassifications 82 (918 ) Amounts reclassified from accumulated other comprehensive loss - - Ending Balance $ (3,818 ) $ (3,207 )

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions to Form 10 10 X. not may six June 30, 2019 not December 31, 2018, 10 March 11, 2019.
Consolidation, Policy [Policy Text Block]	Consolidation Our consolidated financial statements include the accounts of LeMaitre Vascular and the accounts of our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Our revenue is derived primarily from the sale of disposable or implantable devices used during vascular surgery. We sell primarily directly to hospitals and to a lesser extent to distributors, as described below, and, during the periods presented in our consolidated financial statements, entered into consigned inventory arrangements with either hospitals or distributors on a limited basis. With the acquisition of the RestoreFlow allograft business, we also derive revenues from the processing and cryopreservation of human tissues for implantation in patients. These revenues are recognized when services have been provided and the tissue has been shipped to the customer, provided all other revenue recognition criteria discussed in the succeeding paragraph have been met. We recognize revenue under the provisions of ASU 2014 09, Revenue from Contracts with Customers (Topic 606 606 Step 1: Step 2: Step 3: Step 4: Step 5: Revenue is recognized when or as a company satisfies a performance obligation by transferring a promised good or service to a customer (which is when the customer obtains control of that good or service). In instances in which shipping and handling activities are performed after a customer takes control of the goods (such as when title passes upon shipment from our dock), we have made the policy election allowed under Topic 606 not We generally reference customer purchase orders to determine the existence of a contract. Orders that are not one not We recognize revenue, net of allowances for returns and discounts, fees paid to group purchasing organizations, and any sales and value added taxes required to be invoiced, which we have elected to exclude from the measurement of the transaction price as allowed by the standard, at the time of shipment (taking into consideration contractual shipping terms), or in the case of consigned inventory, when it is consumed. Shipment is the point at which control of the product and title passes to our customers, and at which LeMaitre Vascular has a present right to receive payment for the goods. Below is a disaggregation of our revenue by major geographic area, which is among the primary categorizations used by management in evaluating financial performance, for the periods indicated (in thousands): Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 ($ in thousands) ($ in thousands) Americas $ 17,511 $ 16,082 $ 33,886 $ 31,942 Europe, Middle East and Africa 10,014 9,074 20,027 17,829 Asia/Pacific Rim 1,958 1,864 4,049 3,243 Total $ 29,483 $ 27,020 $ 57,962 $ 53,014 Except as discussed in Note 7, not no not 30 60 no Customers returning products may 18 twelve 30 not not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements On January 1, 2019 No. 2016 02, Leases (Topic 842 2018 11, Leases (Topic 842 not January 1, 2019. $7.0 $6.5 $0.5 no 6 In August 2018, 2018 15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350 40 January 1, 2020, not In August 2018, 2018 13 820 January 1, 2020, not In January 2017, 2017 04, 2” not January 1, 2020, not In June 2016, No. 2016 13, 326 2016 13” January 1, 2020, not

Note 1 - Organization and Bas_2

Note 1 - Organization and Basis for Presentation (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 ($ in thousands) ($ in thousands) Americas $ 17,511 $ 16,082 $ 33,886 $ 31,942 Europe, Middle East and Africa 10,014 9,074 20,027 17,829 Asia/Pacific Rim 1,958 1,864 4,049 3,243 Total $ 29,483 $ 27,020 $ 57,962 $ 53,014

Note 2 - Income Tax Expense (Ta

Note 2 - Income Tax Expense (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Six months ended June 30, 2019 (in thousands) Unrecognized tax benefits as of December 31, 2018 $ 711 Additions for tax positions of current year 37 Additions for tax positions of prior years 5 Reductions for settlements with taxing authorities - Reductions for lapses of the applicable statutes of limitations - Unrecognized tax benefits as of June 30, 2019 $ 753

Note 3 - Inventories and Othe_2

Note 3 - Inventories and Other Deferred Costs (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2019 December 31, 2018 (in thousands) Raw materials $ 4,399 $ 4,085 Work-in-process 5,477 5,095 Finished products 18,824 16,391 Other deferred costs 3,544 1,817 Total inventory and other deferred costs $ 32,243 $ 27,388

Note 4 - Acquisitions and Div_2

Note 4 - Acquisitions and Divestitures (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Allocated Fair Value (in thousands) Inventory € 2,419 Land and building 750 Equipment and supplies 94 Intangible assets 623 Bargain purchase gain (1,946 ) Purchase price € 1,940 Allocated Fair Value (in thousands) Inventory $ 739 Equipment and supplies 416 Intangible assets 6,527 Goodwill 6,361 Purchase price $ 14,043
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	Allocated Fair Value Weighted Average Useful Life (in thousands) (in years) Customer relationships € 250 16.0 Intellectual property 237 5.0 Non-compete agreement 46 5.0 Tradenames 90 5.0 Total intangible assets € 623 Allocated Fair Value Weighted Average Useful Life (in thousands) (in years) Customer relationships $ 4,475 16.0 Intellectual property 1,316 7.0 Non-compete agreement 530 5.0 Tradenames 206 7.0 Total intangible assets $ 6,527
Disposal Groups, Including Discontinued Operations [Table Text Block]	Allocated Fair Value (in thousands) Inventory $ 308 Deferred revenue - transition services agreement 1,081 Goodwill 135 Gain on divestiture 5,876 Consideration received $ 7,400

Note 5 - Goodwill and Other I_2

Note 5 - Goodwill and Other Intangibles (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Goodwill [Table Text Block]	(in thousands) Balance at December 31, 2018 $ 29,868 Effects of currency exchange (8 ) Balance at June 30, 2019 $ 29,860
Schedule of Finite-Lived Intangible Assets [Table Text Block]	June 30, 2019 December 31, 2018 Gross Net Gross Net Carrying Accumulated Carrying Carrying Accumulated Carrying Value Amortization Value Value Amortization Value (in thousands) Product technology and intellectual property $ 11,728 $ 6,252 $ 5,476 $ 11,728 $ 5,726 $ 6,002 Trademarks, tradenames and licenses 2,246 1,626 620 2,246 1,561 685 Customer relationships 10,093 3,920 6,173 10,065 3,806 6,259 Other intangible assets 2,143 1,780 363 2,145 1,399 746 Total identifiable intangible assets $ 26,210 $ 13,578 $ 12,632 $ 26,184 $ 12,492 $ 13,692
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 (in thousands) (in thousands) Amortization expense $ 556 $ 414 $ 1,111 $ 832
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ended December 31, 2019 2020 2021 2022 2023 2024 (in thousands) Amortization expense $ 1,010 $ 1,857 $ 1,624 $ 1,420 $ 1,346 $ 1,182

Note 6 - Leases (Tables)

Note 6 - Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Lease, Cost [Table Text Block]	Three months ended Six months ended June 30, 2019 June 30, 2019 (in thousands) (in thousands) Lease cost Operating lease cost $ 432 $ 854 Short-term lease cost 63 131 Total lease cost $ 495 $ 985 Other information Cash paid for amounts included in the measurement of operating lease liabilities $ 445 $ 959 Right-of-use assets obtained in exchange for new operating leae liabilities $ 594 $ 810 Weighted average remaining lease term - operating leases (in years) 4.1 4.1 Weighted average discount rate - operating leases (in years) 5.25 % 5.25 %
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Remainder of 2019 $ 1,080 Year ending December 31, 2020 1,997 2021 1,863 2022 1,522 2023 1,249 Adjustment to net present value as of June 30, 2019 (861 ) Minimum noncancelable lease liability $ 6,850

Note 7 - Accrued Expenses and_2

Note 7 - Accrued Expenses and Other Long-term Liabilities (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	June 30, 2019 December 31, 2018 (in thousands) Compensation and related taxes $ 6,476 $ 7,973 Income and other taxes 1,230 2,927 Professional fees 111 43 Deferred revenue 188 552 Other 4,092 4,352 Total $ 12,097 $ 15,847
Contract with Customer, Asset and Liability [Table Text Block]	June 30, 2019 (in thousands) Beginning contract liability balance $ 552 Revenue recognized upon satisfaction of performance obligations in the period (364 ) Ending balance $ 188
Other Noncurrent Liabilities [Table Text Block]	June 30, 2019 December 31, 2018 (in thousands) Aquisition-related liabilities $ 1,354 $ 1,326 Deferred rent - 530 Income taxes 566 559 Other 146 196 Total $ 2,066 $ 2,611

Note 8 - Segment and Enterpri_2

Note 8 - Segment and Enterprise-wide Disclosures (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	Three months ended Six months ended June 30, June 30, 2019 2018 2019 2018 (in thousands) (in thousands) United States $ 16,006 $ 14,864 $ 30,764 $ 29,684 Germany 3,192 3,257 6,272 6,364 Other countries 10,285 8,899 20,926 16,966 Net Sales $ 29,483 $ 27,020 $ 57,962 $ 53,014

Note 9 - Share-based Compensa_2

Note 9 - Share-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Share-based Payment Arrangement, Cost by Plan [Table Text Block]	Three months ended Six months ended June 30, June 30, 2019 2018 2019 2018 (in thousands) (in thousands) Stock option awards $ 432 $ 391 $ 879 $ 780 Restricted stock units 262 245 561 477 Total share-based compensation $ 694 $ 636 $ 1,440 $ 1,257
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 (in thousands) (in thousands) Cost of sales $ 76 $ 83 $ 158 $ 148 Sales and marketing 146 136 304 273 General and administrative 418 351 837 702 Research and development 54 66 141 134 Total stock-based compensation $ 694 $ 636 $ 1,440 $ 1,257

Note 10 - Net Income Per Share

Note 10 - Net Income Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three months ended Six months ended June 30, June 30, 2019 2018 2019 2018 (in thousands, except per share data) (in thousands, except per share data) Basic: Net income available for common stockholders $ 4,624 $ 8,751 $ 8,137 $ 12,604 Weighted average shares outstanding 19,680 19,320 19,660 19,301 Basic earnings per share $ 0.23 $ 0.45 $ 0.41 $ 0.65 Diluted: Net income available for common stockholders $ 4,624 $ 8,751 $ 8,137 $ 12,604 Weighted-average shares outstanding 19,680 19,320 19,660 19,301 Common stock equivalents, if dilutive 566 940 566 942 Shares used in computing diluted earnings per common share 20,246 20,260 20,226 20,243 Diluted earnings per share $ 0.23 $ 0.43 $ 0.40 $ 0.62 Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive 531 214 537 214

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Dividends Payable [Table Text Block]	Record Date Payment Date Per Share Amount Dividend Payment (in thousands) Fiscal Year 2019 March 22, 2019 April 5, 2019 $ 0.085 $ 1,672 May 22, 2019 June 5, 2019 $ 0.085 $ 1,672 Fiscal Year 2018 March 22, 2018 April 5, 2018 $ 0.070 $ 1,351 May 22, 2018 June 7, 2018 $ 0.070 $ 1,353 August 22, 2018 September 6, 2018 $ 0.070 $ 1,369 November 20, 2018 December 6, 2018 $ 0.070 $ 1,372

Note 12 - Supplemental Cash F_2

Note 12 - Supplemental Cash Flow Information (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Six Months Ended June 30. 2019 2018 (in thousands) Cash paid for income taxes, net $ 4,157 $ 3,140

Note 13 - Fair Value Measurem_2

Note 13 - Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Six months ended June 30, 2019 2018 (in thousands) Beginning balance $ 72 $ 1,300 Additions - - Payments (59 ) (1,142 ) Change in fair value included in earnings (13 ) 42 Ending balance $ - $ 200

Note 14 - Accumulated Other C_2

Note 14 - Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Six months ended June 30, 2019 2018 (in thousands) Beginning balance $ (3,900 ) $ (2,289 ) Other comprehensive income (loss) before reclassifications 82 (918 ) Amounts reclassified from accumulated other comprehensive loss - - Ending Balance $ (3,818 ) $ (3,207 )

Note 1 - Organization and Bas_3

Note 1 - Organization and Basis for Presentation (Details Textual) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Operating Lease, Right-of-Use Asset	$ 6,428
Number of Operating Segments	1
Accounting Standards Update 2016-02 [Member]
Operating Lease, Liability, Total		$ 7,000
Operating Lease, Right-of-Use Asset		6,500
Accrued Rent		$ (500)
Minimum [Member]
Period of Payments Received from Customers	30 days
Maximum [Member]
Period of Payments Received from Customers	60 days

Note 1 - Organization and Bas_4

Note 1 - Organization and Basis for Presentation - Disaggregation of Revenue by Major Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue	$ 29,483	$ 27,020	$ 57,962	$ 53,014
Americas [Member]
Revenue	17,511	16,082	33,886	31,942
EMEA [Member]
Revenue	10,014	9,074	20,027	17,829
Asia Pacific [Member]
Revenue	$ 1,958	$ 1,864	$ 4,049	$ 3,243

Note 2 - Income Tax Expense (De

Note 2 - Income Tax Expense (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Unrecognized Tax Benefits, Ending Balance	$ 753,000	$ 711,000
Domestic Tax Authority [Member]
Open Tax Year	2015 2016 2017 2018
Foreign Tax Authority [Member]
Open Tax Year	2012 2013 2014 2015 2016 2017 2018

Note 2 - Income Tax Expense - R

Note 2 - Income Tax Expense - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)	6 Months Ended
	Jun. 30, 2019USD ($)
Unrecognized tax benefits as of December 31, 2018	$ 711,000
Additions for tax positions of current year	37,000
Additions for tax positions of prior years	5,000
Reductions for settlements with taxing authorities
Reductions for lapses of the applicable statutes of limitations
Unrecognized tax benefits as of June 30, 2019	$ 753,000

Note 3 - Inventories and Othe_3

Note 3 - Inventories and Other Deferred Costs (Details Textual) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross	$ 1.9	$ 1.7

Note 3 - Inventories and Othe_4

Note 3 - Inventories and Other Deferred Costs - Summary of Inventories and Other Deferred Costs (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Raw materials	$ 4,399	$ 4,085
Work-in-process	5,477	5,095
Finished products	18,824	16,391
Other deferred costs	3,544	1,817
Total inventory and other deferred costs	$ 32,243	$ 27,388

Note 4 - Acquisitions and Div_3

Note 4 - Acquisitions and Divestitures (Details Textual) € in Millions, $ in Millions	Jul. 12, 2019USD ($)	Oct. 22, 2018USD ($)	Oct. 22, 2018EUR (€)	Sep. 20, 2018USD ($)	Apr. 05, 2018USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)	Oct. 22, 2018EUR (€)
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life							9 years 255 days
Reddick Divestiture [Member]
Proceeds from Sale of Productive Assets, Total					$ 7.4
Long-term Purchase Commitment, Period					2 years
Gain (Loss) on Disposition of Assets for Financial Service Operations, Total						$ 5.9
Contract with Customer, Liability, Total							$ 0.2
Cardial [Member]
Business Combination, Consideration Transferred, Total		$ 2.3	€ 2
Payments to Acquire Businesses, Gross		1.3	1.1
Business Combination, Consideration Transferred, Liabilities Incurred		0.5	0.5
Business Combination, Deferred Purchase Consideration		0.4						€ 0.4
Deferred Tax Assets, Business Combinations		0.6						€ 0.5
Business Combination, Bargain Purchase, Gain Recognized, Amount		$ 1.6	€ 1.4
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		9 years 146 days	9 years 146 days
Applied Medical [Member]
Business Combination, Consideration Transferred, Total				$ 14.2
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life				13 years
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Deferred Costs				$ 3.2
Acquisition Date Fair Value				$ 3
Business Combination ,Fair Value Inputs, Discount Rate				3.75%
Business Acquisition, Purchase Price Allocation, Goodwill Expected Tax Deductible, Period				15 years
Applied Medical [Member] | Closing Date [Member]
Business Combination, Consideration Transferred, Total				$ 11
Applied Medical [Member] | 12 Months Following the Closing Date [Member]
Business Combination, Consideration Transferred, Total				2
Applied Medical [Member] | 24 Months Following the Closing Date [Member]
Business Combination, Consideration Transferred, Total				$ 1.2
Applied Medical [Member] | UNITED STATES
Percentage of Sales by Major Product Lines				60.00%
Applied Medical [Member] | Foreign [Member]
Percentage of Sales by Major Product Lines				40.00%
Balloon Supply Agreement [Member] | Reddick Divestiture [Member]
Long-term Purchase Commitment, Period					6 years
Tru-Incise Valvulotome [Member] | Subsequent Event [Member]
Business Combination, Consideration Transferred, Total	$ 8

Note 4 - Acquisitions and Div_4

Note 4 - Acquisitions and Divestitures - Assets Acquired and Liabilities Assumed (Details) € in Thousands, $ in Thousands	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)	Oct. 22, 2018EUR (€)	Sep. 20, 2018USD ($)
Goodwill | $	$ 29,860	$ 29,868
Cardial [Member]
Inventory | €			€ 2,419
Land and building | €			750
Equipment and supplies | €			94
Intangible assets | €			623
Bargain purchase gain | €			(1,946)
Purchase price | €			€ 1,940
Applied Medical [Member]
Inventory | $				$ 739
Equipment and supplies | $				416
Intangible assets | $				6,527
Purchase price | $				14,043
Goodwill | $				$ 6,361

Note 4 - Acquisitions and Div_5

Note 4 - Acquisitions and Divestitures - Acquired Intangible Assets and Related Estimated Useful Lives (Details) € in Thousands, $ in Thousands	Oct. 22, 2018EUR (€)	Sep. 20, 2018USD ($)	Jun. 30, 2019
Weighted average useful life (Year)			9 years 255 days
Cardial [Member]
Allocated fair value | €	€ 623
Weighted average useful life (Year)	9 years 146 days
Cardial [Member] | Customer Relationships [Member]
Allocated fair value | €	€ 250
Weighted average useful life (Year)	16 years
Cardial [Member] | Intellectual Property [Member]
Allocated fair value | €	€ 237
Weighted average useful life (Year)	5 years
Cardial [Member] | Noncompete Agreements [Member]
Allocated fair value | €	€ 46
Weighted average useful life (Year)	5 years
Cardial [Member] | Trade Names [Member]
Allocated fair value | €	€ 90
Weighted average useful life (Year)	5 years
Applied Medical [Member]
Allocated fair value | $		$ 6,527
Weighted average useful life (Year)		13 years
Applied Medical [Member] | Customer Relationships [Member]
Allocated fair value | $		$ 4,475
Weighted average useful life (Year)		16 years
Applied Medical [Member] | Intellectual Property [Member]
Allocated fair value | $		$ 1,316
Weighted average useful life (Year)		7 years
Applied Medical [Member] | Noncompete Agreements [Member]
Allocated fair value | $		$ 530
Weighted average useful life (Year)		5 years
Applied Medical [Member] | Trade Names [Member]
Allocated fair value | $		$ 206
Weighted average useful life (Year)		7 years

Note 4 - Acquisitions and Div_6

Note 4 - Acquisitions and Divestitures - Asset Purchase Agreement (Details) - Reddick Divestiture [Member] $ in Thousands	Apr. 05, 2018USD ($)
Inventory	$ 308
Deferred revenue - transition services agreement	1,081
Goodwill	135
Gain on divestiture	5,876
Consideration received	$ 7,400

Note 5 - Goodwill and Other I_3

Note 5 - Goodwill and Other Intangibles (Details Textual)	6 Months Ended
	Jun. 30, 2019
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	9 years 255 days
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	2 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	16 years

Note 5 - Goodwill and Other I_4

Note 5 - Goodwill and Other Intangibles - Schedule of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Balance at December 31, 2018	$ 29,868
Effects of currency exchange	(8)
Balance at June 30, 2019	$ 29,860

Note 5 - Goodwill and Other I_5

Note 5 - Goodwill and Other Intangibles - Components of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Gross carrying value	$ 26,210	$ 26,184
Accumulated amortization	13,578	12,492
Net carrying value	12,632	13,692
Product Technology and Intellectual Property [Member]
Gross carrying value	11,728	11,728
Accumulated amortization	6,252	5,726
Net carrying value	5,476	6,002
Trademarks, Tradenames and Licenses [Member]
Gross carrying value	2,246	2,246
Accumulated amortization	1,626	1,561
Net carrying value	620	685
Customer Relationships [Member]
Gross carrying value	10,093	10,065
Accumulated amortization	3,920	3,806
Net carrying value	6,173	6,259
Other Intangible Assets [Member]
Gross carrying value	2,143	2,145
Accumulated amortization	1,780	1,399
Net carrying value	$ 363	$ 746

Note 5 - Goodwill and Other I_6

Note 5 - Goodwill and Other Intangibles - Amortization Expense Included in General and Administrative Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Amortization expense	$ 556	$ 414	$ 1,111	$ 832

Note 5 - Goodwill and Other I_7

Note 5 - Goodwill and Other Intangibles - Estimated Amortization Expense for Each of Five Succeeding Fiscal Years (Details) $ in Thousands	Jun. 30, 2019USD ($)
2019	$ 1,010
2020	1,857
2021	1,624
2022	1,420
2023	1,346
2023	$ 1,182

Note 6 - Leases (Details Textua

Note 6 - Leases (Details Textual) $ in Thousands	Jun. 30, 2019USD ($)ft²
Capital Leased Assets, Gross, Total | $	$ 0
Lessee, Operating Lease, Discount Rate	5.25%
CANADA
Lessee, Operating Lease, Renewal Term	5 years
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facilities [Member]
Property Subject to or Available for Operating Lease, Number of Units	3
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility One [Member]
Area of Real Estate Property	27,098
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility Two [Member]
Area of Real Estate Property	27,289
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility Three [Member]
Area of Real Estate Property	15,642
Principal Worldwide Executive, Distribution, and Manufacturing Operations Facility Four [Member] | Massachusetts [Member]
Area of Real Estate Property	12,878
International Operations Headquarter Facility [Member] | GERMANY
Area of Real Estate Property	16,470
Additional Area of Real Estate Property Added	3,630
Leased Automobiles [Member]
Lessee, Operating Lease, Term of Contract	3 years

Note 6 - Leases - Additional Le

Note 6 - Leases - Additional Lease Information (Details) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2019USD ($)
Lease cost
Operating lease cost	$ 432	$ 854
Short-term lease cost	63	131
Total lease cost	495	985
Cash paid for amounts included in the measurement of operating lease liabilities	445	959
Right-of-use assets obtained in exchange for new operating leae liabilities	$ 594	$ 810
Weighted average remaining lease term - operating leases (in years) (Year)	4 years 36 days	4 years 36 days
Weighted average discount rate - operating leases (in years)	5.25%	5.25%

Note 6 - Leases - Minimum Renta

Note 6 - Leases - Minimum Rental Commitments (Details) $ in Thousands	Jun. 30, 2019USD ($)
Remainder of 2019	$ 1,080
2020	1,997
2021	1,863
2022	1,522
2023	1,249
Adjustment to net present value as of June 30, 2019	(861)
Minimum noncancelable lease liability	$ 6,850

Note 7 - Accrued Expenses and_3

Note 7 - Accrued Expenses and Other Long-term Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Compensation and related taxes	$ 6,476	$ 7,973
Income and other taxes	1,230	2,927
Professional fees	111	43
Deferred revenue	188	552
Other	4,092	4,352
Total	$ 12,097	$ 15,847

Note 7 - Accrued Expenses and_4

Note 7 - Accrued Expenses and Other Long-term Liabilities - Deferred Revenue (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Beginning contract liability balance	$ 552
Revenue recognized upon satisfaction of performance obligations in the period	(364)
Ending balance	$ 188

Note 7 - Accrued Expenses and_5

Note 7 - Accrued Expenses and Other Long-term Liabilities - Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Aquisition-related liabilities	$ 1,354	$ 1,326
Deferred rent		530
Income taxes	566	559
Other	146	196
Total	$ 2,066	$ 2,611

Note 8 - Segment and Enterpri_3

Note 8 - Segment and Enterprise-wide Disclosures (Details Textual)	6 Months Ended
	Jun. 30, 2019
Number of Operating Segments	1

Note 8 - Segment and Enterpri_4

Note 8 - Segment and Enterprise-wide Disclosures - Net Sales to Unaffiliated Customers by Geography (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net Sales	$ 29,483	$ 27,020	$ 57,962	$ 53,014
UNITED STATES
Net Sales	16,006	14,864	30,764	29,684
GERMANY
Net Sales	3,192	3,257	6,272	6,364
Other Countries [Member]
Net Sales	$ 10,285	$ 8,899	$ 20,926	$ 16,966

Note 9 - Share-based Compensa_3

Note 9 - Share-based Compensation (Details Textual) - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0	0
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	141,000	92,000

Note 9 - Share-based Compensa_4

Note 9 - Share-based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Stock-based compensation	$ 694	$ 636	$ 1,440	$ 1,257
Share-based Payment Arrangement, Option [Member]
Stock-based compensation	432	391	879	780
Restricted Stock Units (RSUs) [Member]
Stock-based compensation	$ 262	$ 245	$ 561	$ 477

Note 9 - Share-based Compensa_5

Note 9 - Share-based Compensation - Schedule of Stock-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Total stock-based compensation	$ 694	$ 636	$ 1,440	$ 1,257
Cost of Sales [Member]
Total stock-based compensation	76	83	158	148
Selling and Marketing Expense [Member]
Total stock-based compensation	146	136	304	273
General and Administrative Expense [Member]
Total stock-based compensation	418	351	837	702
Research and Development Expense [Member]
Total stock-based compensation	$ 54	$ 66	$ 141	$ 134

Note 10 - Net Income per Shar_2

Note 10 - Net Income per Share - Computation of Basic and Diluted Net Income per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Basic:
Net income	$ 4,624	$ 3,513	$ 8,751	$ 3,853	$ 8,137	$ 12,604
Weighted average shares outstanding (in shares)	19,680		19,320		19,660	19,301
Basic earnings per share (in dollars per share)	$ 0.23		$ 0.45		$ 0.41	$ 0.65
Diluted:
Net income	$ 4,624	$ 3,513	$ 8,751	$ 3,853	$ 8,137	$ 12,604
Weighted average shares outstanding (in shares)	19,680		19,320		19,660	19,301
Common stock equivalents, if dilutive (in shares)	566		940		566	942
Shares used in computing diluted earnings per common share (in shares)	20,246		20,260		20,226	20,243
Diluted earnings per share (in dollars per share)	$ 0.23		$ 0.43		$ 0.40	$ 0.62
Shares excluded in computing diluted earnings per share as those shares would be anti-dilutive (in shares)	531		214		537	214

Note 11 - Stockholders' Equit_2

Note 11 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Jul. 22, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Feb. 14, 2019
Common Stock, Dividends, Per Share, Declared		$ 0.085	$ 0.07	$ 0.17	$ 0.14
Subsequent Event [Member]
Common Stock, Dividends, Per Share, Declared	$ 0.085
Dividends Payable	$ 1.7
Dividends Payable, Date Declared	Jul. 22, 2019
Dividends Payable, Date to be Paid	Sep. 5, 2019
Dividends Payable, Date of Record	Aug. 21, 2019
Stock Repurchase Program [Member] | Common Stock [Member]
Stock Repurchase Program, Authorized Amount						$ 10

Note 11 - Stockholders' Equit_3

Note 11 - Stockholders' Equity - Dividend Activity (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Per share amount (in dollars per share)	$ 0.085	$ 0.07	$ 0.17	$ 0.14
Quarterly Dividends 1 [Member]
Record date			Apr. 5, 2019	Apr. 5, 2018
Per share amount (in dollars per share)			$ 1,672	$ 1,351
Quarterly Dividends 2 [Member]
Record date			Jun. 5, 2019	Jun. 7, 2018
Per share amount (in dollars per share)			$ 1,672	$ 1,353
Quarterly Dividends 3 [Member]
Record date				Sep. 6, 2018
Per share amount (in dollars per share)				$ 1,369
Quarterly Dividends 4 [Member]
Record date				Dec. 6, 2018
Per share amount (in dollars per share)				$ 1,372

Note 12 - Supplemental Cash F_3

Note 12 - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash paid for income taxes, net	$ 4,157	$ 3,140

Note 13 - Fair Value Measurem_3

Note 13 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	Mar. 18, 2016	Jun. 30, 2019	Nov. 10, 2016
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Assets, Fair Value Disclosure		$ 0
Fair Value, Inputs, Level 3 [Member] | Restore Flow Allografts [Member]
Acquisition Date Fair Value			$ 1,000
Fair Value, Inputs, Level 3 [Member] | Restore Flow Allografts [Member] | Earn Out Payment [Member]
Business Combination, Contingent Consideration, Liability, Total			4,000
Fair Value, Inputs, Level 3 [Member] | Restore Flow Allografts [Member] | Non-employee Investors [Member]
Business Combination, Contingent Consideration, Liability, Total			1,100
Fair Value, Inputs, Level 3 [Member] | Restore Flow Allografts [Member] | Maximum [Member]
Business Combination, Contingent Consideration, Liability, Total			$ 5,100
Fair Value, Inputs, Level 3 [Member] | ProCol Biologic Graft [Member]
Business Combination Contingent Consideration Measurement as Percentage of Revenue	10.00%
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred	$ 300

Note 13 - Fair Value Measurem_4

Note 13 - Fair Value Measurements - Rollforward of the Fair Value as Determined by Level 3 (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Beginning balance	$ 72	$ 1,300
Additions
Payments	(59)	(1,142)
Change in fair value included in earnings	(13)	42
Ending balance		$ 200

Note 14 - Accumulated Other C_3

Note 14 - Accumulated Other Comprehensive Income Loss - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Balance	$ 130,235	$ 109,770
Balance	137,537	120,744
AOCI Attributable to Parent [Member]
Balance	(3,900)	(2,289)
Other comprehensive income (loss) before reclassifications	82	(918)
Amounts reclassified from accumulated other comprehensive loss
Balance	$ (3,818)	$ (3,207)